GuillermoGarcia-ManeroMD

Oncology • Houston, TX

Hematologic Oncology

Professor, Hematology, University of Texas Medical School at Houston

Join to view full profile

Dr. Garcia-Manero is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Garcia-Manero's full profile

Already have an account?

Office
1515 Holcombe Blvd
Houston, TX 77030
Phone+1 713-792-6161
Is this information wrong?

Education & Training

Sidney Kimmel Medical College at Thomas Jefferson University/TJUHFellowship, Hematology and Medical Oncology, 1996 - 1999
Sidney Kimmel Medical College at Thomas Jefferson University/TJUHResidency, Internal Medicine, 1993 - 1996
Universidad de Zaragoza Faculty of MedicineClass of 1991

Certifications & Licensure

FL State Medical License 2021 - Present
AZ State Medical License 2024 - 2025
OK State Medical License 2020 - 2025
TN State Medical License 2024 - 2025
GA State Medical License 2024 - 2025
WA State Medical License 2024 - 2024
AL State Medical License 2024 - 2024
TX State Medical License 2000 - 2024
MS State Medical License 2024 - 2024
PA State Medical License 1994 - 2014
American Board of Internal Medicine Medical Oncology
Join now to see all

Awards, Honors, & Recognition

America's Top Doctors Castle Connolly, 2014
America's Top Doctors for Cancer Castle Connolly, 2013
Super Doctor SuperDoctors.com

Clinical Trials

Phase I/II Study of Decitabine and Valproic Acid in Relapsed/Refractory Leukemia or Myelodysplastic Syndromes Start of enrollment: 2004 Jan 23
Completed
Phase 1, Phase 2
Phase II 5-Azacytidine Plus VPA Plus ATRA Start of enrollment: 2005 Jul 01
Completed
Phase 2
Vorinostat and Idarubicin in Treating Patients With Relapsed or Refractory Leukemia or Myelodysplastic Syndromes Start of enrollment: 2006 Mar 01
Completed
Phase 1
A Study of Low-Dose Decitabine in Relapsed or Refractory Acute Lymphocytic Leukemia (ALL) Start of enrollment: 2006 Jul 01
Completed
Phase 1
Azacytidine With Valproic Acid Versus Ara-C in Acute Myeloid Leukemia (AML)/ Myelodysplastic Syndrome (MDS) Patients Start of enrollment: 2005 Aug 01
Completed
Phase 2
Phase II Study of Idarubicin, Cytarabine, and Vorinostat With High-Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) Start of enrollment: 2008 Apr 01
Completed
Phase 2
A Phase I Dose Escalation Study of Oral SB939 Administered Alone or With Azacitidine Start of enrollment: 2007 Apr 01
Completed
Phase 1
PR1 Vaccination in Myelodysplastic Syndrome (MDS) Start of enrollment: 2006 Jul 01
Terminated
Phase 2
Decitabine and Clofarabine in Higher Risk Myelodysplastic Syndromes (MDS) Start of enrollment: 2010 Jan 01
Completed
Phase 2
Study of LBH589 for Patients With Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS) Start of enrollment: 2009 Aug 01
Terminated
Phase 2
Myelodysplastic Syndromes (MDS) Event Free Survival With Iron Chelation Therapy Study Start of enrollment: 2010 Mar 22
Completed
Phase 2
Vorinostat in Combination With Azacitidine in Patients With Newly-Diagnosed Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndrome (MDS) Start of enrollment: 2009 Sep 08
Completed
Phase 2
5-Azacytidine With Lenalidomide in Patients With High Risk Myelodysplastic Syndrome (MDS) and Acute Myelogenous Leukemia (AML) Start of enrollment: 2009 Dec 01
Completed
Phase 1, Phase 2
Clinical Study of PM01183 in Patients With Acute Leukemia or Relapsed/Refractory Myelodysplastic Syndrome Start of enrollment: 2011 May 01
Completed
Phase 1
SB1518 for Patients With Myelodysplastic Syndrome (MDS) Start of enrollment: 2011 Dec 01
Terminated
Phase 2
Clofarabine Plus Low-Dose Cytarabine for Patients With Higher-Risk Myelodysplastic Syndrome (MDS) Start of enrollment: 2011 Nov 16
Completed
Phase 2
Phase I Study of the Combination of 5-azacytidine With Valproic Acid and All-trans Retinoic Acid in Patients With High Risk Myelodysplastic Syndrome and Acute Myelogenous Leukemia Start of enrollment: 2005 Jul 01
A Phase 1, Open-Label, Dose-Escalation & Expanded Cohort, Continuous IV Infusion, Multi-center Study of the Safety, Tolerability,PK & PD of EPZ-5676 in Treatment Relapsed/Refractory Patients With Leukemias Involving Start of enrollment: 2012 Sep 01
Completed
Phase 1
Cytarabine and Daunorubicin Hydrochloride or Idarubicin and Cytarabine With or Without Vorinostat in Treating Younger Patients With Previously Untreated Acute Myeloid Leukemia Start of enrollment: 2013 Feb 12
Completed
Phase 3
Phase 2 Study of Pracinostat With Azacitidine in Patients With Previously Untreated Myelodysplastic Syndrome Start of enrollment: 2013 Jun 01
Completed
Phase 2
Bortezomib for Low or Intermediate-1 Myelodysplastic Syndrome (MDS) With p65 Activation Start of enrollment: 2013 Aug 07
Completed
Phase 2
Ruxolitinib for Patients With Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS) Start of enrollment: 2014 Feb 01
Completed
Phase 1
Safety and Efficacy Study of Pracinostat With Azacitadine in Elderly Patients With Newly Diagnosed Acute Myeloid Leukemia (AML) Start of enrollment: 2013 Dec 24
Completed
Phase 2
Phase II Part 2 Expansion of Oral Rigosertib in Combination With Azacitidine Start of enrollment: 2013 Aug 01
Completed
Phase 1, Phase 2
Efficacy and Safety of IV Rigosertib in MDS Patients With Excess Blasts Progressing After Azacitidine or Decitabine Start of enrollment: 2013 Aug 01
Completed
Phase 3
Phase 2 Study Adding Pracinostat to a Hypomethylating Agent (HMA) in Patients With MDS Who Failed to Respond to Single Agent HMA Start of enrollment: 2013 Dec 01
Completed
Phase 2
Guadecitabine in Treating Patients With Higher-Risk Myelodysplastic Syndromes Start of enrollment: 2014 Nov 10
Active, not recruiting
Phase 2
Phase II Study to Evaluate Overall Response in Patients With Higher Risk Myelodysplastic Syndromes (MDS) Treated With Azacitidine With or Without Deferasirox. Start of enrollment: 2014 Sep 11
Terminated
Phase 2
Study of FF-10501-01 in Patients With Relapsed or Refractory Hematological Malignancies Start of enrollment: 2014 Jul 01
Completed
Phase 1, Phase 2
Controlled Study of Rigosertib Versus Physician's Choice of Treatment in MDS Patients After Failure of an HMA Start of enrollment: 2015 Dec 02
Terminated
Phase 3
Azacitidine and Pembrolizumab in Treating Patients With Myelodysplastic Syndrome Start of enrollment: 2017 Nov 06
Active, not recruiting
Phase 2
A Safety and Efficacy Study of Pracinostat and Azacitidine in Patients With High Risk Myelodysplastic Syndromes Start of enrollment: 2017 Jun 01
Terminated
Phase 2
An Efficacy and Safety Study Of Pracinostat In Combination With Azacitidine In Adults With Acute Myeloid Leukemia Start of enrollment: 2017 Jun 23
Terminated
Phase 3
A Phase II, Open-Label, Study of Subcutaneous Canakinumab, an Anti-IL-1β Human Monoclonal Antibody, for Patients With Low or Int-1 Risk IPSS/IPSS-R Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia Start of enrollment: 2020 Aug 25
Recruiting
Phase 2
Dose Escalation/ Expansion Study of CA-4948 as Monotherapy in Patients With AML or MDS Start of enrollment: 2020 Jul 06
Recruiting
Phase 1, Phase 2
Venetoclax and Azacitidine for the Treatment of Relapsed or Refractory High-Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia Start of enrollment: 2020 Sep 04
Recruiting
Phase 1, Phase 2
Nivolumab and/or Ipilimumab With or Without Azacitidine in Treating Patients With Myelodysplastic Syndrome Start of enrollment: 2015 Sep 08
Active, not recruiting
Phase 2
Roles: Contact, Principal Investigator
Venetoclax in Combination With ASTX727 for the Treatment of Treatment-Naive High-Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia Start of enrollment: 2021 Jan 19
Recruiting
Phase 1, Phase 2
Roles: Contact, Principal Investigator
Venetoclax and Azacitidine for the Treatment of High-Risk Recurrent or Refractory Myelodysplastic Syndrome Start of enrollment: 2019 Oct 01
Recruiting
Phase 1, Phase 2
Roles: Principal Investigator, Contact
Study of the Safety, Tolerability and Efficacy of KPT-8602 in Participants With Relapsed/Refractory Cancer Indications Start of enrollment: 2016 Jan 01
Active, not recruiting
Phase 1, Phase 2
Roles: Contact, Principal Investigator
Study of the ZN-d5 and ZN-c3 in Subjects With Acute Myeloid Leukemia (AML) Start of enrollment: 2022 Dec 01
Recruiting
Phase 1, Phase 2
Roles: Contact
Join now to see all

Publications & Presentations

PubMed

Exploring the landscape of somatic ASXL2 mutations in myeloid neoplasms: Frequency and clinical implications.
Tareq Abuasab, Gautam Borthakur, Rashmi Kanagal-Shamanna, Lucia Masarova, Keyur Patel, Koichi Takahashi, Prithviraj Bose, John Villarreal, Sherry Pierce, Tapan Kadia, ...> ;American Journal of Hematology. 2024 Apr 13
Combination of dasatinib and venetoclax in newly diagnosed chronic phase chronic myeloid leukemia.
Elias Jabbour, Fadi G Haddad, Koji Sasaki, Bing Z Carter, Yesid Alvarado, Cedric Nasnas, Lewis Nasr, Lucia Masarova, Naval Daver, Naveen Pemmaraju, Nicholas J Short, J...> ;Cancer. 2024 Apr 9
Sotatercept for anemia of myelofibrosis: a phase II investigator-initiated study.
Prithviraj Bose, Lucia Masarova, Naveen Pemmaraju, Sharon D Bledsoe, Naval G Daver, Elias J Jabbour, Tapan M Kadia, Zeev Estrov, Steven M Kornblau, Michael Andreeff, N...> ;Haematologica. 2024 Apr 4
Targetable genetic abnormalities in patients with acute myeloblastic leukemia across age groups.
Alex Bataller, Courtney D DiNardo, Alexandre Bazinet, Naval G Daver, Abhishek Maiti, Gautam Borthakur, Nicholas Short, Koji Sasaki, Elias J Jabbour, Ghayas C Issa, Nav...> ;American Journal of Hematology. 2024 Apr 1
1 citations
Reduced dose azacitidine plus venetoclax as maintenance therapy in acute myeloid leukaemia following intensive or low-intensity induction: a single-centre, single-arm,...
Alexandre Bazinet, Hagop Kantarjian, Alex Bataller, Naveen Pemmaraju, Gautam Borthakur, Kelly Chien, Yesid Alvarado, Prithviraj Bose, Elias Jabbour, Musa Yilmaz, Court...> ;The Lancet. Haematology. 2024 Apr 1
Genomic determinants of response and resistance to inotuzumab ozogamicin in B-cell ALL.
Yaqi Zhao, Nicholas J Short, Hagop M Kantarjian, Ti-Cheng Chang, Pankaj S Ghate Ph.D, Chunxu Qu, Walid Macaron, Nitin Jain, Beenu Thakral, Aaron Phillips, Joseph D Kho...> ;Blood. 2024 Mar 29
Therapy-related chronic myelomonocytic leukemia does not have the high-risk features of a therapy-related neoplasm.
Alex Bataller, Georgina Gener-Ricos, Emmanuel Almanza, Kelly Sharon Chien, Samuel Urrutia, Alexandre Bazinet, Juan Jose Rodriguez-Sevilla, Danielle Hammond, Koji Sasak...> ;Blood Advances. 2024 Mar 21
Hematopoietic stem cells with granulo-monocytic differentiation state overcome venetoclax sensitivity in patients with myelodysplastic syndromes.
Juan Jose Rodriguez-Sevilla, Irene Ganan-Gomez, Feiyang Ma, Kelly Chien, Monica Del Rey, Sanam Loghavi, Guillermo Montalban-Bravo, Vera Adema, Bethany Wildeman, Rashmi...> ;Nature Communications. 2024 Mar 18
Pracinostat combined with azacitidine in newly diagnosed adult acute myeloid leukemia (AML) patients unfit for standard induction chemotherapy: PRIMULA phase III study.
Maciej Kazmierczak, Agnieszka Wierzbowska, Chun Yew Fong, Michael K Keng, Gianluca Ballinari, Francesco Scarci, Lionel Adès, Guillermo Garcia-Manero> ;Leukemia Research. 2024 Mar 12
Association between class III obesity and overall survival in previously untreated younger patients with acute myeloid leukemia enrolled on SWOG S1203.
Michelle Zhang, Megan Othus, Kerry McMillen, John Pagel, Mary-Elizabeth Percival, Harry Erba, Guillermo Garcia-Manero, Mohamed Sorror> ;Research Square. 2024 Mar 11
Myeloid neoplasm with <10% blasts and t(3;5)(q25.1;q34)/NPM::MLF1: A classification dilemma.
Fnu Sameeta, Hong Fang, Wei Wang, Zhenya Tang, Sa A Wang, Gokce A Toruner, Xenia Parisi, Joseph D Khoury, Ghayas Issa, Guillermo Garcia-Manero, L Jeffrey Medeiros, Gui...> ;American Journal of Hematology. 2024 Mar 5
Oral decitabine and cedazuridine plus venetoclax for older or unfit patients with acute myeloid leukaemia: a phase 2 study.
Alexandre Bazinet, Guillermo Garcia-Manero, Nicholas Short, Yesid Alvarado, Alex Bataller, Tareq Abuasab, Rabiul Islam, Kathryn Montalbano, Ghayas Issa, Abhishek Maiti...> ;The Lancet. Haematology. 2024 Apr 1
Cancer patients with clonal hematopoiesis die from primary malignancy or comorbidities despite higher rates of transformation to myeloid neoplasms.
Ziyi Li, Rashmi Kanagal-Shamanna, Guillermo Montalban-Bravo, Danielle Hammond, Sherry A Pierce, Kelly S Chien, Faustine Ong, Kunhwa Kim, Courtney D DiNardo, Koichi Tak...> ;Cancer Medicine. 2024 Mar 1
Influence of co-mutational patterns in disease phenotype and clinical outcomes of chronic myelomonocytic leukemia.
Guillermo Montalban-Bravo, Juan Jose Rodriguez-Sevilla, David Michael Swanson, Rashmi Kanagal-Shamanna, Danielle Hammond, Kelly Chien, Koji Sasaki, Elias Jabbour, Cour...> ;Leukemia. 2024 Feb 28
Targeting DNA2 overcomes metabolic reprogramming in multiple myeloma.
Natthakan Thongon, Feiyang Ma, Natalia Baran, Pamela Lockyer, Jintan Liu, Christopher Jackson, Ashley Rose, Ken Furudate, Bethany Wildeman, Matteo Marchesini, Valentin...> ;Nature Communications. 2024 Feb 8
1 citations
Oral decitabine plus cedazuridine and venetoclax in patients with higher-risk myelodysplastic syndromes or chronic myelomonocytic leukaemia: a single-centre, phase 1/2...
Bataller, A., Montalban-Bravo, G., Bazinet, A., Alvarado, Y., Chien, K., Venugopal, S., Ishizawa, J., Hammond, D., Swaminathan, M., Sasaki, K., Issa, G., Short, N., Ma...> ;The Lancet. Haematology. 2024 Mar 1
Cytogenetic and Molecular Associations with Outcomes in Higher-Risk Myelodysplastic Syndromes Treated with Hypomethylating Agents plus Venetoclax.
Alexandre Bazinet, Sai Prasad Desikan, Ziyi Li, Juan Jose Rodriguez-Sevilla, Sangeetha Venugopal, Samuel Urrutia, Guillermo Montalban-Bravo, Koji Sasaki, Kelly S Chien...> ;Clinical Cancer Research. 2024 Apr 1
Azacitidine, Venetoclax, and Gilteritinib in Newly Diagnosed and Relapsed or Refractory-Mutated AML.
Short, N., Daver, N., Dinardo, C., Kadia, T., Nasr, L., Macaron, W., Yilmaz, M., Borthakur, G., Montalban-Bravo, G., Garcia-Manero, G., Issa, G., Chien, K., Jabbour, E...> ;Journal of Clinical Oncology. 2024 Jan 26
Clinical evaluation of complete remission (CR) with partial hematologic recovery (CRh) in acute myeloid leukemia: a report of 7235 patients from seven cohorts.
Jacob S Appelbaum, Andrew H Wei, Sumithra J Mandrekar, Ing S Tiong, Chong Chyn Chua, Tse-Chieh Teh, Chun Yew Fong, Stephen B Ting, Daniela Weber, Axel Benner, Hannah H...> ;Leukemia. 2024 Feb 1
3 citations
Oral decitabine-cedazuridine versus intravenous decitabine for myelodysplastic syndromes and chronic myelomonocytic leukaemia (ASCERTAIN): a registrational, randomised...
Garcia-Manero, G., McCloskey, J., Griffiths, E., Yee, K., Zeidan, A., Al-Kali, A., Deeg, H., Patel, P., Sabloff, M., Keating, M., Zhu, N., Gabrail, N., Fazal, S., Maly...> ;The Lancet. Haematology. 2024 Jan 1
1 citations
Prognostic risk signature in patients with acute myeloid leukemia treated with hypomethylating agents and venetoclax.
Bataller, A., Bazinet, A., DiNardo, C., Maiti, A., Borthakur, G., Daver, N., Short, N., Jabbour, E., Issa, G., Pemmaraju, N., Yilmaz, M., Montalban-Bravo, G., Takahash...> ;Blood Advances. 2024 Feb 27
1 citations
Phase Ib study of sabatolimab (MBG453), a novel immunotherapy targeting TIM-3 antibody, in combination with decitabine or azacitidine in high- or very high-risk myelod...
Andrew M Brunner, Jordi Esteve, Kimmo Porkka, Steve Knapper, Elie Traer, Sebastian Scholl, Guillermo Garcia-Manero, Norbert Vey, Martin Wermke, Jeroen J W M Janssen, R...> ;American Journal of Hematology. 2024 Feb 1
Phase 1/2 study of CPX-351 for patients with Int-2 or high risk International Prognostic Scoring System myelodysplastic syndromes and chronic myelomonocytic leukaemia ...
Guillermo Montalban-Bravo, Elias Jabbour, Gautam Borthakur, Tapan Kadia, Farhad Ravandi, Kelly Chien, Naveen Pemmaraju, Danielle Hammond, Xiao Qin Dong, Xuelin Huang, ...> ;British Journal of Haematology. 2024 Mar 1
1 citations
A randomized phase III study of standard versus high-dose cytarabine with or without vorinostat for AML.
Guillermo Garcia-Manero, Nikolai A Podoltsev, Megan Othus, John M Pagel, Jerald P Radich, Min Fang, David A Rizzieri, Guido Marcucci, Stephen A Strickland, Mark R Litz...> ;Leukemia. 2024 Jan 1
1 citations
Long-term utilization and benefit of luspatercept in transfusion-dependent, erythropoiesis-stimulating agent-refractory or -intolerant patients with lower-risk myelody...
Uwe Platzbecker, Valeria Santini, Rami S Komrokji, Amer M Zeidan, Guillermo Garcia-Manero, Rena Buckstein, Dimana Miteva, Karen Keeperman, Natalia Holot, Jose Alberto ...> ;Leukemia. 2023 Nov 1
Join now to see all

Abstracts/Posters

Loss of EZH2 Protein Expression in Myelodysplastic Syndrome Correlates with EZH2 Mutation and Portends a Worse Outcome
Guillermo Garcia-Manero, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Characteristics and Clinical Outcomes of Patients with Acute Lymphoblastic Leukemia with KMT2A (MLL) Rearrangement
Guillermo Garcia-Manero, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Phase 1 Dose Escalation and Expansion Study to Determine Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the BET Inhibitor FT-1101 As a Single Agent in...
Guillermo Garcia-Manero, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Activity of Multiple Targetable Therapies in FLT3-Mutated (mu) Acute Myeloid Leukemia (AML) Patients (pts) with Concurrent Isocitrate Dehydrogenase Mutation (IDHm)
Guillermo Garcia-Manero, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Sequential Combination of Inotuzumab Ozogamicin (InO) with Low-Intensity Chemotherapy (Mini-hyper-CVD) with or without Blinatumomab Is Highly Effective in Patients (pt...
Guillermo Garcia-Manero, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Long-Term Safety and Efficacy of Hyper-CVAD Plus Ponatinib As Frontline Therapy for Adults with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia
Guillermo Garcia-Manero, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Assessment of Longer-Term Efficacy and Safety in the Phase 3, Randomized, Double-Blind, Placebo-Controlled MEDALIST Trial of Luspatercept to Treat Anemia in Patients (...
Guillermo Garcia-Manero, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Diagnostic Testing Patterns and Concordance with World Health Organization (WHO) Criteria for Patients (Pts) with Newly Diagnosed (ND) Myelodysplastic Syndromes (MDS) ...
Guillermo Garcia-Manero, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Outcome of Patients (Pts) with Philadelphia Chromosome-Positive (Ph+) Acute Lymphoblastic Leukemia (ALL) without 3-Month Complete Molecular Response (CMR)
Guillermo Garcia-Manero, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Venetoclax Combined with Cladribine + Low Dose AraC (LDAC) Alternating with 5-Azacytidine Produces High Rates of Minimal Residual Disease (MRD) Negative Complete Remis...
Guillermo Garcia-Manero, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Activity of Venetoclax-Based Therapy in Myelodysplastic Syndrome (MDS)
Guillermo Garcia-Manero, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Value of Minimal Residual Disease (MRD) Monitoring Using Real-Time Quantitative PCR in Patients with Acute Promyelocytic Leukemia (APL) Treated with ATRA, ATO, +/- GO
Guillermo Garcia-Manero, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Characteristics and Outcomes of Therapy-Related Versus De Novo Acute Myeloid Leukemia with Normal Karyotype
Guillermo Garcia-Manero, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Ten-Day Decitabine with Venetoclax (DEC10-VEN) in Acute Myeloid Leukemia: Updated Results of a Phase II TrialClinically Relevant Abstract
Guillermo Garcia-Manero, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Liposomal Cytarabine and Daunorubicin (CPX-351) in Combination with Gemtuzumab Ozogamicin (GO) in Relapsed Refractory (R/R) Patients with Acute Myeloid Leukemia (AML) ...
Guillermo Garcia-Manero, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Comprehensive DNA 5-Hydroxymethylation Landscapes in Myelodysplastic Syndromes (MDS)
Guillermo Garcia-Manero, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Long-Term Follow up of a Randomized Phase 2 Study of Low-Dose Decitabine Versus Low-Dose Azacitidine in Lower-Risk Myelodysplastic Syndromes
Guillermo Garcia-Manero, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Phase II Study of Blinatumomab in Patients with B-Cell Acute Lymphoblastic Leukemia (B-ALL) with Positive Measurable Residual Disease (MRD)
Guillermo Garcia-Manero, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
A Phase II Trial of Azacitidine (AZA) in Combination with Ruxolitinib (RUX) in Myelodysplastic Syndrome/Myeloproliferative Neoplasms (MDS/MPNs)
Guillermo Garcia-Manero, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Phase 2 Study of Ruxolitinib (RUX) in Combination with 5-Azacitidine (AZA) in Patients (pts) with Myelofibrosis
Guillermo Garcia-Manero, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Outcomes in Molecular Subgroups and Resistance Patterns with Ten-Day Decitabine and Venetoclax (DEC10-VEN) in Acute Myeloid Leukemia
Guillermo Garcia-Manero, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Outcomes of Patients with Suboptimal /Warning Response to Tyrosine Kinase Inhibitors: A Comparison of the 2009 and 2013 Guidelines of the European Leukemianet
Guillermo Garcia-Manero, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Results of a Clinical Trial of H3B-8800, a Splicing Modulator, in Patients with Myelodysplastic Syndromes (MDS), Acute Myeloid Leukemia (AML) or Chronic Myelomonocytic...
Guillermo Garcia-Manero, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
The Early Achievement of Measurable Residual Disease Negativity in the Treatment of Adults with Philadelphia-Negative B-Cell Acute Lymphoblastic Leukemia Is a Strong P...
Guillermo Garcia-Manero, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Early Intervention with Hypomethylating Agents in Transfusion-Independent Patients with Myelodysplastic Syndrome
Guillermo Garcia-Manero, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Join now to see all

Lectures

Hematologic Improvement_Neutrophil and _Platelet in the MEDALIST Trial: Multilineage Data from a Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Luspate...
61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
Genomic Profiling in Patients with Higher-Risk Myelodysplastic Syndrome (HR-MDS) Following HMA Failure: Baseline Results from the Inspire Study (04-30)
61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
A Phase 3 Randomized Study (PRIMULA) of the Epigenetic Combination of Pracinostat, a Pan-Histone Deacetylase (HDAC) Inhibitor, with Azacitidine (AZA) in Patients with ...
61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
Phase 3, Multi-Center, International, Randomized, Double-Blind, Placebo Controlled Study of Oral Rigosertib + Injectable Azacitidine (AZA) Versus Injectable Azacitidin...
61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
A phase I study of AMV564 in patients with intermediate or high-risk myelodysplastic syndromes.
2019 ASCO Annual Meeting - 6/1/2019
Induced PD-1 Expression on Bone Marrow CD34+ Cells from MDS Patients Treated with 5-Azacitadine in Combination with Nivolumab and/or Ipilimumab
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Imapct of Clonal Hematopoiesis of Indeterminate Potential (CHIP) Associated Mutations and Risk of Comorbidities in Patients with Myelodysplastic Syndrome
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Predicting Induction Toxicity with 7+3: Analysis of SWOG Trial S1203
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Cell-Type Specific Mechanisms of Hematopoietic Stem Cell (HSC) Expansion Underpin Progressive Disease in Myelodysplastic Syndromes (MDS) and Provide a Rationale for Ta...
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Diverse Landscape of TET2 Variants in MDS and AML
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Results of a Phase 1, Dose-Escalation Study of FF-10501-01 in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML) or Hypomethylating Agent (HMA)-Resistant M...
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Pan-Myeloid Leukemia Analysis: Machine Learning-Based Approach to Predict Phenotype and Clinical Outcomes Using Mutation Data
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Inotuzumab Ozogamicin in Combination with Low-Intensity Chemotherapy (mini-hyper-CVD) Vs. Standard Intensive Chemotherapy (hyper-CVAD) As Frontline Therapy for Older P...
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Long Term Results of a Randomized Phase 2 Dose-Response Study of Guadecitabine, a Novel Subcutaneous (SC) Hypomethylating Agent (HMA), in 102 Patients with Intermediat...
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Five-Day Versus Ten-Day Schedules of Decitabine in Older Patients with Newly Diagnosed Acute Myeloid Leukemia: Results of a Randomized Phase II Study
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
A Phase II Study of the Hyper-CVAD Regimen in Sequential Combination with Blinatumomab As Frontline Therapy for Adults with B-Cell Acute Lymphoblastic Leukemia (B-ALL)
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Phase 2 Expansion Study of Oral Rigosertib Combined with Azacitidine (AZA) in Patients (Pts) with Higher-Risk (HR) Myelodysplastic Syndromes (MDS): Efficacy and Safety...
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Safety and Efficacy, Including Event-Free Survival, of Deferasirox Versus Placebo in Iron-Overloaded Patients with Low- and Int-1-Risk Myelodysplastic Syndromes (MDS):...
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Telomere Damage Maintains Hematopoietic Stem Cells (HSCs) in an Activated Metabolic State, Which Compromises Their Self-Renewal Capability
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Final Report of a Phase II Study of Guadecitabine (SGI-110) in Patients (pts) with Previously Untreated Myelodysplastic Syndrome (MDS)
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Evolutionary Action Score of Missense TP53 Mutations Can Predict Outcome in Patients with Myelodysplastic Syndrome and Acute Myeloid Leukemia
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Mutational and Clonal Landscape of Acute Myeloid Leukemia with Myelodysplastic Related Changes
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Double Immune Checkpoint Inhibitor Blockade with Nivolumab and Ipilimumab with or without Azacitidine in Patients with Myelodysplastic Syndrome (MDS)
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Ultrasensitive Duplex Sequencing of Pretreatment ABL1 Kinase Domain Mutations in Patients with Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leu...
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Chemoimmunotherapy with Inotuzumab Ozogamicin Combined with Mini-Hyper-CVD, with or without Blinatumomab, for Newly Diagnosed Older Patients with Philadelphia Chromoso...
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Join now to see all

Authored Content

Clinical Experience of Venetoclax Combinations for Relapsed/Refractory Myeloid MalignanciesOctober 2017
The Combination of Quizartinib with Azacitidine or Low Dose Cytarabine Is Highly Active in Patients (Pts) with FLT3-ITD Mutated Myeloid Leukemias: Interim Report of a Phase I/II TrialOctober 2017
Randomized Phase II Study of Guadecitabine (SGI-110) Based Regimens Comparing Guadecitabine 5 Days (SGI5), 10 Days (SGI10), 5 Days + Idarubicin (SGI5 + Ida), and 5 Days + Cladribine (SGI5 + Clad), in Previously Untreated Patients ≥ 70 Years with Acute Myeloid Leukemia (AML)–a Bayesian DesignOctober 2017
A Phase I/II Study of Selinexor (SEL) with Sorafenib in Patients (Pts) with Relapsed and/or Refractory (R/R) FLT3 Mutated Acute Myeloid Leukemia (AML)October 2017
Join now to see all

Press Mentions

Monoclonal Antibody Reduced Need for Transfusions in Low-Risk MDSMay 25th, 2023
ASCO: Bristol Myers' $4B Plan for Reblozyl Takes Shape in Blood Cancer Anemia—with One CaveatMay 25th, 2023
What's on Tap at the Society of Hematologic Oncology's 10th Annual MeetingSeptember 26th, 2022
Join now to see all